Biosino Announces First-in-Human Dosing of LV009, a Novel In Vivo CAR-T/NK Therapy Targeting CD19
PersonGen
Developer of Tumor Cell Immunotherapy Technologies and Products
▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register
Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Please feel free to point out in the comments. This article is only for the introduction of drugs related to medical health.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。
PharmaCircleMonitoring shows:Bo Sheng Ji's self-developed in-vivo cell therapy product, LV009 injection, has completed the first patient dosing, marking the official transition of Bo Sheng Ji’s CAR-T/NK technology from "ex vivo customization" to a new era of "in vivo generation."LV009 Achieves Efficient Transfection of Resting T Cells and NK Cells Through Breakthrough Lentiviral Vector Technology, Simultaneously Generating CD19-Targeted CAR-T and CAR-NK Cells。
Core Technology Breakthrough:
Efficient Transfection of Resting Cells:LV009 adopts a lentiviral vector that breaks through the limitations of traditional technology, enabling highly efficient transfection of resting T cells and NK cells without prior activation of immune cells, and generating CAR-T and CAR-NK cells with significant cytotoxic capabilities.
Two-cell Synergistic Mechanism:By synchronously generating CAR-T and CAR-NK, a complementary immune-killing network is formed, which is expected to overcome tumor escape and enhance the durability of efficacy;
Intelligent Regulation Design:The directional expression system carried by the vector can precisely guide the expression of CAR in target cells, demonstrating excellent tissue specificity;
Establishment of a Clinical-Grade Lentivirus Platform: According to the "Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products(Trial)》, Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD has established a dedicated quality system for in vivo lentivirus production, laying a solid quality foundation for the clinical application of this new type of product.
▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register
▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register
Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Please feel free to point out in the comments. This article is only for the introduction of drugs related to medical health.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。
PharmaCircleMonitoring shows:Bo Sheng Ji's self-developed in-vivo cell therapy product, LV009 injection, has completed the first patient dosing, marking the official transition of Bo Sheng Ji’s CAR-T/NK technology from "ex vivo customization" to a new era of "in vivo generation."LV009 Achieves Efficient Transfection of Resting T Cells and NK Cells Through Breakthrough Lentiviral Vector Technology, Simultaneously Generating CD19-Targeted CAR-T and CAR-NK Cells。
Core Technology Breakthrough:
Efficient Transfection of Resting Cells:LV009 adopts a lentiviral vector that breaks through the limitations of traditional technology, enabling highly efficient transfection of resting T cells and NK cells without prior activation of immune cells, and generating CAR-T and CAR-NK cells with significant cytotoxic capabilities.
Two-cell Synergistic Mechanism:By synchronously generating CAR-T and CAR-NK, a complementary immune-killing network is formed, which is expected to overcome tumor escape and enhance the durability of efficacy;
Intelligent Regulation Design:The directional expression system carried by the vector can precisely guide the expression of CAR in target cells, demonstrating excellent tissue specificity;
Establishment of a Clinical-Grade Lentivirus Platform: According to the "Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products(Trial)》, Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD has established a dedicated quality system for in vivo lentivirus production, laying a solid quality foundation for the clinical application of this new type of product.
PharmaCircleMonitoring shows:Bo Sheng Ji's self-developed in-vivo cell therapy product, LV009 injection, has completed the first patient dosing, marking the official transition of Bo Sheng Ji’s CAR-T/NK technology from "ex vivo customization" to a new era of "in vivo generation."LV009 Achieves Efficient Transfection of Resting T Cells and NK Cells Through Breakthrough Lentiviral Vector Technology, Simultaneously Generating CD19-Targeted CAR-T and CAR-NK Cells。
Core Technology Breakthrough:
Efficient Transfection of Resting Cells:LV009 adopts a lentiviral vector that breaks through the limitations of traditional technology, enabling highly efficient transfection of resting T cells and NK cells without prior activation of immune cells, and generating CAR-T and CAR-NK cells with significant cytotoxic capabilities.
Two-cell Synergistic Mechanism:By synchronously generating CAR-T and CAR-NK, a complementary immune-killing network is formed, which is expected to overcome tumor escape and enhance the durability of efficacy;
Intelligent Regulation Design:The directional expression system carried by the vector can precisely guide the expression of CAR in target cells, demonstrating excellent tissue specificity;
Establishment of a Clinical-Grade Lentivirus Platform: According to the "Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products(Trial)》, Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD has established a dedicated quality system for in vivo lentivirus production, laying a solid quality foundation for the clinical application of this new type of product.
More views: https://pharma.bcpmdata.com/，Mo Entropy Medicine Database
Reference:
NMPA/CDE；
Moxie Pharma Database, https://pharma.bcpmdata.com/；
FDA/EMA/PMDA；
Company;
Relevant companies have publicly disclosed (all images in the text are from the official enterprises unless otherwise indicated);
Etc.
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceuticals industry. With the mission of "enabling the borderless flow of intelligence and networks," it has established an empowering system that covers the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it is building the infrastructure for value flow within China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for companies' leapfrog growth.
